MedKoo Cat#: 461981 | Name: PD 082106
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PD 082106 is an inhibitor of FMS-related tyrosine kinase 3 and a derivative of indirubin.

Chemical Structure

PD 082106
PD 082106
CAS#861214-33-7

Theoretical Analysis

MedKoo Cat#: 461981

Name: PD 082106

CAS#: 861214-33-7

Chemical Formula: C16H10FN3O2

Exact Mass: 295.0757

Molecular Weight: 295.27

Elemental Analysis: C, 65.08; H, 3.41; F, 6.43; N, 14.23; O, 10.84

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
10mg USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PD 082106; 5′-Fluoroindirubinoxime; 5’-FIO
IUPAC/Chemical Name
3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-5-fluoro-1,3-dihydro-2H-indol-2-one
InChi Key
RJIBTAMXAXHIAN-UJZLGWIISA-N
InChi Code
InChI=1S/C16H10FN3O2/c17-8-5-6-12-10(7-8)13(16(21)19-12)15-14(20-22)9-3-1-2-4-11(9)18-15/h1-7,18,22H,(H,19,21)/b15-13-,20-14-
SMILES Code
O=C1NC2=C(C=C(F)C=C2)/C1=C3NC4=C(C=CC=C4)C/3=N/O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
5'-Fluoroindirubinoxime (5’-FIO, compound 13), an Indirubin (HY-N0117) derivative, is a potent FLT3 inhibitor, with an IC50 of 15 nM.
In vitro activity:
Among several 5 and 5'-substituted indirubin derivatives, 5-fluoro analog, 13 exhibited potent inhibitory activity at FLT3 (IC(50)=15 nM) with more than 100-fold selectivity versus 6 other kinases and potent anti-proliferative effect for MV4;11 cells (IC(50)=72 nM) with 30-fold selectivity versus RS4;11 cells. Cell cycle analysis indicated that compound 13 induced cell cycle arrest at G(0)/G(1) phase in MV4;11 cells. Reference: Bioorg Med Chem Lett. 2010 Mar 15;20(6):2033-7. https://pubmed.ncbi.nlm.nih.gov/20153646/
In vivo activity:
The novel indirubin derivatives 5'-nitro-indirubinoxime, 5'-fluoro-indirubinoxime, and 5'-trimethylacetamino-indirubinoxime were designed and tested for antitumor activity both in vitro and in vivo using rat tumor model. Indirubin derivatives showed strong antitumor activity in rat solid and oral tumor models. Direct injection of indirubin derivatives every other day for 10 days induced significant inhibition of tumor growth in Sprague-Dawley rats bearing RK3E-ras-induced tumors. Histologically, treatment with indirubin derivatives caused significant inhibition of tumor formation with increased apoptosis and decreased tumor cell proliferation. Reference: Clin Cancer Res. 2007 Jan 1;13(1):253-9. https://pubmed.ncbi.nlm.nih.gov/17200363/
Solvent mg/mL mM
Solubility
DMSO 71.2 241.01
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 295.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Choi SJ, Moon MJ, Lee SD, Choi SU, Han SY, Kim YC. Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells. Bioorg Med Chem Lett. 2010 Mar 15;20(6):2033-7. doi: 10.1016/j.bmcl.2010.01.039. Epub 2010 Jan 20. PMID: 20153646. 2. Kim SA, Kim YC, Kim SW, Lee SH, Min JJ, Ahn SG, Yoon JH. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res. 2007 Jan 1;13(1):253-9. doi: 10.1158/1078-0432.CCR-06-1154. PMID: 17200363.
In vitro protocol:
Choi SJ, Moon MJ, Lee SD, Choi SU, Han SY, Kim YC. Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells. Bioorg Med Chem Lett. 2010 Mar 15;20(6):2033-7. doi: 10.1016/j.bmcl.2010.01.039. Epub 2010 Jan 20. PMID: 20153646.
In vivo protocol:
Kim SA, Kim YC, Kim SW, Lee SH, Min JJ, Ahn SG, Yoon JH. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res. 2007 Jan 1;13(1):253-9. doi: 10.1158/1078-0432.CCR-06-1154. PMID: 17200363.
1: Choi SJ, Lee JE, Jeong SY, Im I, Lee SD, Lee EJ, Lee SK, Kwon SM, Ahn SG, Yoon JH, Han SY, Kim JI, Kim YC. 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. doi: 10.1021/jm100080z. PubMed PMID: 20361800. 2: Jung ME, Byun BJ, Kim HM, Lee JY, Park JH, Lee N, Son YH, Choi SU, Yang KM, Kim SJ, Lee K, Kim YC, Choi G. Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening. Bioorg Med Chem Lett. 2016 Jun 1;26(11):2719-23. doi: 10.1016/j.bmcl.2016.03.111. Epub 2016 Apr 1. PubMed PMID: 27106709. 3: Moon MJ, Lee SK, Lee JW, Song WK, Kim SW, Kim JI, Cho C, Choi SJ, Kim YC. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorg Med Chem. 2006 Jan 1;14(1):237-46. Epub 2005 Sep 22. PubMed PMID: 16182537. 4: Kim SA, Kim YC, Kim SW, Lee SH, Min JJ, Ahn SG, Yoon JH. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res. 2007 Jan 1;13(1):253-9. PubMed PMID: 17200363. 5: Krivogorsky B, Grundt P, Yolken R, Jones-Brando L. Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs. Antimicrob Agents Chemother. 2008 Dec;52(12):4466-9. doi: 10.1128/AAC.00903-08. Epub 2008 Sep 29. PubMed PMID: 18824607; PubMed Central PMCID: PMC2592 Lister, T., Mizia, R., Erickson, A., & Trowbridge, T. (2007). Electrochemical Corrosion Testing of Neutron Absorber Materials (No. INL/EXT-06-11772). Idaho National Lab.(INL), Idaho Falls, ID (United States).